Entera Bio grants 140,000 options to CFO
Entera Bio Ltd. reported a grant of stock options to its Chief Financial Officer covering 140,000 ordinary shares at an exercise price of $1.37 per share, expiring on 2036-05-07.
Rhea-AI Filing Summary
Entera Bio Ltd. reported a grant of stock options to its Chief Financial Officer covering 140,000 ordinary shares at an exercise price of $1.37 per share, expiring on 2036-05-07. The Board approved the grant on May 7, 2026, subject to filing a Registration Statement on Form S-8 for the underlying ordinary shares, which occurred on August 7, 2026. The options vest over three years beginning May 7, 2026, with one third vesting on May 7, 2027 and the remaining two thirds vesting quarterly, subject to full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 140,000 shares
Grant/Award
1 txn
Insider
Yaacov-Garbeli Dana
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 140,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 140,000 contracts (Direct)
Footnotes (1)
- F1. Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).
Key Figures
Stock options granted: 140000.0000
Exercise price: 1.3700
Expiration date: 2036-05-07
+2 more
5 metrics
Stock options granted
140000.0000
Number of stock options granted to the Chief Financial Officer
Exercise price
1.3700
Exercise price per ordinary share for the granted options
Expiration date
2036-05-07
Expiration date of the CFO’s stock option grant
Board approval date
2026-05-07
Date the Board of Directors approved the option grant
Grant transaction date
2026-08-07
Transaction date reported for the stock option grant
Key Terms
Stock Option (right to buy), Registration Statement on Form S-8, Change in Control, 2018 Equity Incentive Plan
4 terms
Stock Option (right to buy) financial
"Security title listed as "Stock Option (right to buy)" in the transaction."
Registration Statement on Form S-8 regulatory
"Subject to the filing of a Registration Statement on Form S-8 registering shares."
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
Change in Control financial
"Subject to full acceleration upon a Change in Control as defined in the plan."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2018 Equity Incentive Plan financial
"Change in Control as defined in the Company's 2018 Equity Incentive Plan."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options did Entera Bio (ENTX) grant to its CFO?
Entera Bio granted its CFO stock options over 140,000 ordinary shares at an exercise price of $1.37 per share. The options are reported as a direct holding and expire on 2036-05-07 under the company’s equity incentive plan.
What is the vesting schedule for the Entera Bio (ENTX) CFO option grant?
The options vest over three years starting May 7, 2026, with one third vesting on May 7, 2027 and the remaining two thirds vesting ratably on a quarterly basis thereafter. Vesting is subject to the CFO’s continued service, with full acceleration upon a qualifying Change in Control.
When were the Entera Bio (ENTX) CFO options approved and reported?
The Board approved the grant on May 7, 2026, subject to filing a Form S-8 for the underlying ordinary shares, which occurred on August 7, 2026. The transaction date reported for the grant is 2026-08-07.
What triggers acceleration of the Entera Bio (ENTX) CFO option vesting?
All unvested options become fully vested upon a Change in Control, as defined in Entera Bio’s 2018 Equity Incentive Plan. This means a qualifying corporate transaction could accelerate remaining vesting, rather than following the standard three-year, quarterly vesting schedule for the CFO.
Does the Entera Bio (ENTX) filing indicate a Rule 10b5-1 trading plan?
No. The Rule 10b5-1 checkbox is not selected, and the grant is described as Board-approved executive compensation rather than a trading plan transaction. It represents options awarded to the CFO, not market purchases or sales under a pre-arranged plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
